06/01/10PIVOTAL DATA FOR THE INVESTIGATIONAL TREATMENT PSD502 FOR PRIMARY PREMATURE EJACULATION IN THE UNITED STATES TO BE PRESENTED AT MAJOR MEDICAL MEETING
05/26/10Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s PSD502, an Investigational Treatment For Primary Premature Ejaculation
04/01/10Shionogi’s Nitrolingual® Pumpspray is Available for Angina Pectoris Patients
HomeFortametAltoprevCompany ProfileProductsSamplesInvestor RelationsOpportunitiesContact UsSularPrenateProductsTriglideLatest News and Events